Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men
Monika Sarkar, Katherine Yates, Ayako Suzuki, Joel Lavine, Ryan Gill, Toni Ziegler, Norah Terrault, Sandeep Dhindsa, Monika Sarkar, Katherine Yates, Ayako Suzuki, Joel Lavine, Ryan Gill, Toni Ziegler, Norah Terrault, Sandeep Dhindsa
Abstract
With rising prevalence of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) is now a leading cause of chronic liver disease. One-third of obese or diabetic men have subnormal free and bioavailable testosterone concentrations.1 Several studies have further shown low testosterone to be associated with imaging-confirmed NAFLD in men,2 although it is unknown whether low testosterone confers increased risk of more clinically relevant manifestations of NAFLD, including nonalcoholic steatohepatitis (NASH) and NASH fibrosis. We therefore aimed to evaluate the association of testosterone with histologic features of NAFLD among a representative cohort of men from the multicenter NASH Clinical Research Network (NASH CRN).
Conflict of interest statement
Conflict of Interest:
MS: Site PI for an industry sponsored NAFLD clinical trial (Zydus Pharmaceuticals).
KY: nothing to disclose
AS: nothing to disclose
JL: Consultant for Merck, Novo Nordisk, and Pfizer, grant support from Genfit.
RG: nothing to disclose
TZ: nothing to disclose
NT: Advisory board Intercept; institutionalization grant support Gilead.
SD: Bayer (consultant), site PI for a pharmaceutical multicenter trial (TRAVERSE) to evaluate cardiovascular events after testosterone therapy, sponsored by Abbvie.
No authors have any personal conflicts of interest to disclose.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
References
- Dhindsa S, Ghanim H, Batra M, and Dandona P. Hypogonadotropic Hypogonadism in Men With Diabesity. Diabetes Care. 2018;41(7):1516–25.
- Jaruvongvanich V, Sanguankeo A, Riangwiwat T, and Upala S. Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Ann Hepatol. 2017;16(3):382–94.
- Vermeulen A, Verdonck L, and Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–72.
- Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.
- Sarkar M, VanWagner LB, Terry JG, Carr JJ, Rinella M, Schreiner PJ, et al. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. The American journal of gastroenterology. 2019;114(5):758–63.
- Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. Diabetes care. 2016;39(1):82–91.
- Kapoor D, Goodwin E, Channer KS, and Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European journal of endocrinology/European Federation of Endocrine Societies. 2006;154(6):899–906.
- Fujihara Y, Hamanoue N, Yano H, Tanabe M, Akehi Y, Nomiyama T, et al. High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men. Endocr J. 2019.
Source: PubMed